Why Biotechnology Advances Through Structured Non-Closure Companies, organisms, infrastructure, capital, data, and the passages through which scientific possibility becomes medicine The Molecule Leaves the Laboratory A biotechnology program begins by looking smaller than it really is. A sequence appears on a screen. A protein binds. A microbial strain expresses something useful. An engineered cell changes […]
Tag: CMC Strategy
The Trust Layer: Why 2026 Rewards Platforms, Not Point Solutions
2026 is the inflection point where biotechnology stops being priced on promise and starts being priced on conversion. This isn’t a change in sentiment. It’s a change in operating constraints. Capital, regulators, and operators now press the same question: can you keep truth intact as a programme moves from concept to scale—through handoffs, pressure, and […]